Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $14.83 Consensus Target Price from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.8333.

Several research firms have commented on KPTI. Wall Street Zen upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Piper Sandler restated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday. Finally, Royal Bank Of Canada dropped their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, November 4th.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors have recently modified their holdings of the stock. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $45,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics in the second quarter valued at $56,000. Bridgeway Capital Management LLC acquired a new position in Karyopharm Therapeutics in the second quarter valued at $163,000. ADAR1 Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the third quarter worth about $164,000. Finally, Silverback Asset Management LLC grew its holdings in shares of Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Price Performance

KPTI opened at $7.31 on Wednesday. The business has a fifty day moving average price of $6.13 and a 200 day moving average price of $5.65. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $12.45. The stock has a market capitalization of $124.64 million, a price-to-earnings ratio of -0.50 and a beta of 0.23.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The firm had revenue of $44.04 million during the quarter, compared to analyst estimates of $39.56 million. On average, research analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.